Unnamed: 0,title,date,stock,sentiment
1379225.0,Intersect ENT Announces CMS Approves SINUVA Sinus Implant For Reimbursement With New C-Code And Pass-Through Payment Status,2020-06-09 07:05:00-04:00,XENT,positive
1379226.0,"SVB Leerink Maintains Market Perform on Intersect ENT, Raises Price Target to $15",2020-05-12 13:00:00-04:00,XENT,neutral
1379227.0,"JP Morgan Maintains Overweight on Intersect ENT, Lowers Price Target to $18",2020-05-12 11:17:00-04:00,XENT,negative
1379228.0,Canaccord Genuity Downgrades Intersect ENT to Hold,2020-05-12 07:15:00-04:00,XENT,neutral
1379229.0,Intersect ENT Announces $65 Million Convertible Notes Investment from Deerfield Management,2020-05-11 07:39:00-04:00,XENT,neutral
1379230.0,"Intersect ENT Q1 EPS $(0.540) Misses $(0.440) Estimate, Sales $19.800M Miss $23.660M Estimate",2020-05-11 07:11:00-04:00,XENT,negative
1379231.0,Intersect ENT shares are trading lower after Bank Of America downgraded the stock from Buy to Underperfomr and announced a price target of $10 per share.,2020-04-15 08:16:00-04:00,XENT,positive
1379232.0,"B of A Securities Downgrades Intersect ENT to Underperform, Announces $10 Price Target",2020-04-15 07:36:00-04:00,XENT,positive
1379233.0,Intersect ENT Sees Q1 Sales $19.5M-$19.8M; The Company Also Reported To Withdraw Full Year FY20 Guidance,2020-04-13 16:16:00-04:00,XENT,neutral
1379234.0,Intersect ENT ; Raises FY2020 Sales Guidance from $115M-119M to $115M-119M,2020-02-24 07:05:00-05:00,XENT,neutral
1379235.0,"Intersect ENT Q4 EPS $(0.25) Beats $(0.35) Estimate, Sales $31.754M Beat $31.24M Estimate",2020-02-24 07:04:00-05:00,XENT,neutral
1379236.0,"Intersect ENT Sees Prelim. FY19 Sales $109M vs $108.71M Est., Sees FY20 Sales $115M-$119M vs $119.69M Est.",2020-01-13 07:14:00-05:00,XENT,neutral
1379237.0,"JP Morgan Maintains Overweight on Intersect ENT, Raises Price Target to $28",2019-12-20 09:37:00-05:00,XENT,neutral
1379238.0,Intersect ENT Appoints Richard A. Meier EVP And CFO,2019-11-27 07:02:00-05:00,XENT,neutral
1379239.0,Intersect ENT Reaffirms FY19 Sales Flat On Year Over Year Basis,2019-11-01 07:35:00-04:00,XENT,neutral
1379240.0,"Intersect ENT Q3 EPS $(0.41) Misses $(0.39) Estimate, Sales $24.056M Miss $24.06M Estimate",2019-11-01 07:34:00-04:00,XENT,negative
1379241.0,Intersect ENT shares are trading lower after the company's ASCENT trial did not meet its primary endpoint.,2019-10-07 07:58:00-04:00,XENT,neutral
1379242.0,Intersect ENT's ASCENT Trial Did Not Meet its Primary Endpoint,2019-10-07 07:04:00-04:00,XENT,neutral
1379243.0,"Intersect ENT Shares Halted, News Pending",2019-10-07 06:59:00-04:00,XENT,positive
1379244.0,Intersect ENT shares are trading lower after the company reported worse-than-expected Q2 EPS and sales results. The company's stock was also downgraded by multiple firms.,2019-08-02 09:20:00-04:00,XENT,neutral
1379245.0,Guggenheim Downgrades Intersect ENT to Neutral,2019-08-02 08:12:00-04:00,XENT,neutral
1379246.0,"Piper Jaffray Downgrades Intersect ENT to Neutral, Lowers Price Target to $17",2019-08-02 08:04:00-04:00,XENT,negative
1379247.0,"Intersect ENT Q2 EPS $(0.36) Misses $(0.34) Estimate, Sales $26.7M Miss $27.16M Estimate",2019-08-01 16:08:00-04:00,XENT,negative
1379248.0,Intersect ENT Reports FDA Approval Of New PROPEL Mini Straight Delivery System,2019-07-25 16:56:00-04:00,XENT,positive
1379249.0,Northland Securities Upgrades Intersect ENT to Market Perform,2019-07-10 09:07:00-04:00,XENT,positive
1379250.0,"Intersect ENT Reports CFO Jeryl Hilleman To Step Down; Thomas West Named Pres, CEO",2019-06-27 16:08:00-04:00,XENT,neutral
1379251.0,"Berenberg Downgrades Intersect ENT to Hold, Lowers Price Target to $27",2019-06-21 06:44:00-04:00,XENT,negative
1379252.0,Intersect ENT Highlights Publication Of Pooled Analysis of the SINUVA Sinus Implant for Nasal Polyps,2019-06-04 16:23:00-04:00,XENT,neutral
1379253.0,Intersect ENT shares are trading lower after SVB Leerink downgraded the stock from Outperform to Market Perform and lowered the price target from $41 to $29 following the company report of worse-than-expected Q1 EPS. The company also lowered its FY19 sale,2019-05-07 09:33:00-04:00,XENT,negative
1379254.0,"Northland Downgrades Intersect ENT, Inc. - Common Stock to Underperform",2019-05-07 09:06:00-04:00,XENT,neutral
1379255.0,"SVB Leerink Downgrades Intersect ENT, Inc. - Common Stock to Market Perform, Lowers Price Target to $29",2019-05-07 08:36:00-04:00,XENT,negative
1379256.0,Intersect ENT shares are trading lower after the company reported lower-than-expected Q1 EPS results; the company also cut FY19 sales guidance.,2019-05-06 18:31:00-04:00,XENT,negative
1379257.0,Intersect ENT Shares Down 11% Upon Resumption Of Trade,2019-05-06 16:50:00-04:00,XENT,positive
1379258.0,Intersect ENT Reports CEO Lisa Earnhardt To Step Down; Kieran Gallahue Named Exec. Chair And Interim CEO,2019-05-06 16:50:00-04:00,XENT,neutral
1379259.0,Intersect ENT Shares To Resume Trade At 4:40 p.m. EDT,2019-05-06 16:13:00-04:00,XENT,positive
1379260.0,UPDATE: Intersect ENT Cuts FY19 Sales Guidance From $123M-$127M To $113M-$117M vs $ $125.3M Estimate,2019-05-06 16:09:00-04:00,XENT,negative
1379261.0,Intersect ENT Cuts FY19 Sales Guidance,2019-05-06 16:09:00-04:00,XENT,negative
1379262.0,"Intersect ENT Q1 EPS $(0.35) Misses $(0.3) Estimate, Sales $26.673M Beat $26.31M Estimate",2019-05-06 16:08:00-04:00,XENT,negative
1379263.0,Intersect ENT Shares Halted News Pending,2019-05-06 16:03:00-04:00,XENT,positive
1379264.0,"Intersect ENT shares are trading higher after the company on Thursday announced it will present at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 14, 2019.",2019-04-29 13:44:00-04:00,XENT,positive
1379265.0,Intersect ENT Sees Q1 Sales $26M-$26.5M vs $27.5M Estimate; FY19 Sales $123M-$127M vs $127.2M Estimate,2019-02-25 16:49:00-05:00,XENT,neutral
1379266.0,"Intersect ENT Q4 EPS $(0.16), Inline, Sales $32.783M Beat $32.49M Estimate",2019-02-25 16:49:00-05:00,XENT,neutral
1379267.0,Intersect ENT Sees Q1 Sales $26.0M-26.50M vs $28.36M Est,2019-01-07 08:07:00-05:00,XENT,neutral
1379268.0,Intersect ENT Sees FY2019 Sales $123.0M-127.0M vs $128.58M Est,2019-01-07 08:06:00-05:00,XENT,neutral
1379269.0,Intersect ENT Sees Q4 Sales $32.60M-32.80M vs $32.21M Est,2019-01-07 08:06:00-05:00,XENT,neutral
1379270.0,Intersect ENT Sees FY2018 Sales $108.30M-108.50M vs $107.93M Est,2019-01-07 08:05:00-05:00,XENT,neutral
1379271.0,Intersect ENT Announces First Patient Enrolled in ASCEND Study of Investigational Drug-Coated Sinus Balloon,2018-12-17 08:03:00-05:00,XENT,neutral
1379272.0,Intersect ENT Highlights Publication Of Pooled Analysis Of Steriod-Releasing Implants For Patients Following Frontal Sinus Surgery In International Forum of Allergy & Rhinology,2018-11-15 16:47:00-05:00,XENT,neutral
1379273.0,Intersect ENT Reaffirms FY2018 Sales Guidance of $106.0M-109.0M vs $107.36M Est,2018-11-05 07:11:00-05:00,XENT,neutral
1379274.0,"Intersect ENT Q3 EPS $(0.25) Beats $(0.27) Estimate, Sales $24.666M Beat $24.1M Estimate",2018-11-05 07:10:00-05:00,XENT,neutral
1379275.0,Intersect ENT Names Christine Kowalski COO,2018-10-29 09:02:00-04:00,XENT,neutral
1379276.0,Documents Show Anthem Now Covering Reimbursement For Intersect's Sinuva,2018-10-02 10:03:00-04:00,XENT,neutral
1379277.0,"Stocks Which Set New 52-Week Low Yesterday, August 2nd",2018-08-03 11:22:00-04:00,XENT,negative
1379278.0,"Stocks Which Set New 52-Week Low Yesterday, August 1st",2018-08-02 11:07:00-04:00,XENT,negative
1379279.0,"Intersect ENT Sees Q3 Sales $23.8M-$24.3M vs $27.57M Est., FY18 Sales $106M-$109M vs $116.29M Est.",2018-08-01 06:30:00-04:00,XENT,neutral
1379280.0,"Intersect ENT Q2 EPS $(0.14) Beats $(0.17) Estimate, Sales $26.3M Miss $28.15M Estimate",2018-08-01 06:28:00-04:00,XENT,negative
1379281.0,Piper Jaffray Publishes a Positive Note on Intersect ENT Calling the CMS' Decision an Error,2018-05-07 11:24:00-04:00,XENT,positive
1379282.0,Hearing Leerink Also Positive on Intersect ENT,2018-05-07 11:18:00-04:00,XENT,positive
1379283.0,"Watch Shares of Intersect ENT Moving Higher, Hearing JP Morgan Positive on the Stock",2018-05-07 11:06:00-04:00,XENT,positive
1379284.0,Intersect ENT Sees FY2018 Sales $111.0M-116.0M vs $115.40M Est,2018-05-01 17:05:00-04:00,XENT,neutral
1379285.0,"Intersect ENT Q1 EPS $(0.21) Beats $(0.23) Estimate, Sales $24.723M Beat $23.65M Estimate",2018-05-01 17:05:00-04:00,XENT,neutral
1379286.0,Intersect ENT Announces Launch Of SINUVA Sinus Implant In-Office Treatment Option For Recurrent Nasal Polyps,2018-04-02 08:13:00-04:00,XENT,neutral
1379287.0,"Intersect ENT Reports Q4 EPS $(0.11) vs $(0.18) Est., Sales $29.53M vs $28.71M Est.",2018-02-27 16:30:00-05:00,XENT,neutral
1379288.0,Intersect Sees Q1 Sales $23.2M-$23.7M vs $24.4M Est.,2018-01-08 08:50:00-05:00,XENT,neutral
1379289.0,Intersect Sees FY18 Sales $111M-$116M vs $113.8M Est.,2018-01-08 08:50:00-05:00,XENT,neutral
1379290.0,Intersect Sees Q4 Sales $29.3M-$29.5M vs $27.7M Est.; Sees FY17 Sales $96.1M-$96.3M vs $94.5M Est.,2018-01-08 08:50:00-05:00,XENT,neutral
1379291.0,JP Morgan Upgrades Intersect ENT to Overweight,2018-01-02 06:22:00-05:00,XENT,neutral
1379292.0,Intersect ENT Shares To Resume Trade At 8:30 a.m. EST,2017-12-11 08:09:00-05:00,XENT,positive
1379293.0,Intersect ENT Reports FDA Approval Of SINUVA Sinus Implant As Treatment Option For Recurrent Nasal Polyps,2017-12-11 08:00:00-05:00,XENT,positive
1379294.0,Shineco and Intersect ENT Halted News Pending,2017-12-11 07:58:00-05:00,XENT,neutral
1379295.0,Intersect ENT Shares Halted News Pending,2017-12-11 07:55:00-05:00,XENT,positive
1379296.0,Deerfield Management Reports 5.9% Stake In Intersect ENT,2017-11-16 14:28:00-05:00,XENT,neutral
1379297.0,Intersect ENT Reports FDA Performed Pre-Approval Inspection Of Co.'s Menlo Park Facility,2017-11-06 08:12:00-05:00,XENT,neutral
1379298.0,Intersect ENT Sees Q4 Sales $27.3M-$27.8M vs $26.89M Est.,2017-11-02 17:31:00-04:00,XENT,neutral
1379299.0,"Intersect ENT Reports Q3 EPS $(0.15) vs $(0.19) Est., Sales $22.3M vs $21.51M Est.",2017-11-02 17:30:00-04:00,XENT,neutral
1379300.0,Intersect ENT Sees Q3 Sales $21M-$21.5M vs $20.85M Est.; FY17 Sales $91M-$93M vs $90.37M Est.,2017-08-01 17:18:00-04:00,XENT,neutral
1379301.0,"Intersect ENT Reports Q2 EPS $(0.08) vs $(0.19) Est., Sales $24M vs $22.61M Est.",2017-08-01 17:17:00-04:00,XENT,neutral
1379302.0,Northland Securities Downgrades Intersect ENT to Market Perform,2017-05-31 09:11:00-04:00,XENT,positive
1379303.0,Intersect ENT Sees Q2 Sales $22.5M-$22.7M vs $21.7M Est.; Raises FY17 Sales Outlook from $87M-$89M to $89M-$91M vs $88M Est.,2017-05-02 17:44:00-04:00,XENT,neutral
1379304.0,"Intersect ENT Reports Q1 EPS $(0.23) vs $(0.25) Est., Sales $20.474M vs $19.38M Est.",2017-05-02 17:05:00-04:00,XENT,neutral
1379305.0,Intersect ENT Submits NDA To FDA For Office-Based RESOLVE Steroid Releasing Implant,2017-03-08 08:08:00-05:00,XENT,positive
1379306.0,"Deutsche Bank Upgrades Intersect ENT To Buy, Raises Price Target To $19",2017-03-06 06:14:00-05:00,XENT,neutral
1379307.0,"Intersect ENT Reports Q4 EPS $(0.17) vs $(0.20) Est., Sales $24.2M vs $23.47M Est.",2017-02-28 16:35:00-05:00,XENT,neutral
1379308.0,Intersect ENT Reports FDA Approval of PROPEL Contour,2017-02-24 08:01:00-05:00,XENT,positive
1379309.0,"Intersect ENT Sees Prelim Q4 Rev. $24-$24.2M vs. Est. $23M, FY16 Rev. $78.5-$78.7M vs. Est. $77.4M",2017-01-09 08:05:00-05:00,XENT,neutral
1379310.0,"Guggenheim Earlier Initiated Coverage On Intersect ENT at Buy, Announced $20.00 Target",2016-12-07 10:42:00-05:00,XENT,neutral
1379311.0,"JP Morgan Downgrades Intersect ENT, Inc. - Common Stock to Neutral",2016-11-02 05:36:00-04:00,XENT,positive
1379312.0,Deutsche Bank Initiates Coverage on Intersect ENT at Hold,2016-10-06 05:53:00-04:00,XENT,neutral
1379313.0,"Northland Securities Initiates Coverage on Intersect ENT at Outperform, Announces $26.00 PT",2016-03-29 08:54:00-04:00,XENT,positive
1379314.0,"Leerink Swann Reiterates Outperform on Intersect ENT, Raises PT to $38.00",2015-06-17 07:51:00-04:00,XENT,neutral
1379315.0,"Canaccord Genuity Maintains Buy on Intersect ENT, Raises PT to $32.00",2015-06-09 16:46:00-04:00,XENT,neutral
1379316.0,Intersect ENT Announces Prices Upsized 3.582M Share Offering @$25.00/Share,2015-06-03 04:38:00-04:00,XENT,positive
1379317.0,Intersect ENT Files S-1 Registration Statement for Proposed 3M Share Offering,2015-05-20 20:33:00-04:00,XENT,positive
1379318.0,"CRT Capital Initiates Coverage on Intersect ENT at Buy, Announces $32.00 PT",2015-04-09 06:07:00-04:00,XENT,neutral
1379319.0,"Canaccord Genuity Initiates Coverage on Intersect ENT at Buy, Announces $27.00 PT",2015-03-16 05:16:00-04:00,XENT,neutral
1379320.0,Intersect ENT Sees FY2014 Sales $38.40M-38.60M,2015-01-12 16:08:00-05:00,XENT,neutral
1379321.0,Intersect ENT Sees Q4 Sales $13.20M-13.40M,2015-01-12 16:07:00-05:00,XENT,neutral
1379322.0,"Intersect ENT, Inc. Reports Q2 EPS of $(2.36) vs $(0.28) Est; Revenue of $8.57M vs $8.46M Est",2014-09-03 16:03:00-04:00,XENT,neutral
1379323.0,Benzinga's Top Initiations ,2014-08-18 09:10:00-04:00,XENT,positive
1379324.0,JP Morgan Initiates Intersect ENT With Overweight,2014-08-18 08:45:00-04:00,XENT,neutral
1379325.0,"JP Morgan Initiates Coverage on Intersect ENT, Inc. at Overweight, Announces $22.00 PT",2014-08-18 06:30:00-04:00,XENT,neutral
1379326.0,"Leerink Swann Initiates Coverage on Intersect ENT, Inc. at Outperform, Announces $20.00 PT",2014-08-18 06:29:00-04:00,XENT,neutral
1379327.0,"Piper Jaffray Initiates Coverage on Intersect ENT, Inc. at Overweight, Announces $20.00 PT",2014-08-18 06:29:00-04:00,XENT,negative
1379328.0,"Intersect ENT Shares Open for Trade at $13.20/Share, IPO Priced at $11",2014-07-24 10:53:00-04:00,XENT,positive
1379329.0,Intersect Announces 5M Share IPO Priced at $11/Share,2014-07-24 08:08:00-04:00,XENT,positive
1379330.0,"IPO Lookout: Lots of Action This Week, But Is Anything A Worthwhile Investment?",2014-07-21 16:37:00-04:00,XENT,positive
1379331.0,Intersect ENT Expects 5M Share IPO to Price $11.00-$13.00/Share,2014-07-14 06:26:00-04:00,XENT,positive
